Iron absorption during epoetin alfa therapy for chemotherapy-associated anaemia

Cancer Investigation

Volumn 24, Issue 6, 2006, Pages 562-566

  Savonije, J H ^a   Van Groeningen, C J ^a   Van Den Broek, W J M ^b   Rentinck, M E M ^a   Corstens, F H M ^b   Gundy, C ^a   Giaccone, G ^a   Marx, J J M ^c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Chemotherapy; Epoetin alfa; Iron absorption

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; FERRITIN; FERROUS ION; OXALIPLATIN; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ADULT; AGED; ANEMIA; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; IRON ABSORPTION; IRON DEFICIENCY; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SOLID TUMOR;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; EPOETIN ALFA; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; INTESTINAL ABSORPTION; IRON; MALE; MIDDLE AGED; NEOPLASMS; ORGANOPLATINUM COMPOUNDS;

EID: 33748856829     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900600894757     Document Type: Article

References (11)

1. Groopman, J.E.; Itri, L.M. Chemotherapy-induced in adults: incidence and treatment. J. Natl. Cancer Inst. 1999, 19, 1616-1634.
2. Cella, D. Factors influencing quality of life in cancer patients: Anemia and fatigue. Sem. Oncol. 1998, 25, 43-46.
3. Rizzo, J.D.; Lichtin, A.E. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J. Clin. Oncol. 2002, 20, 4083-4107.
4. Fishbane, S.; Frei, G.L.; Maesaka, J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am. J. Kidney Dis. 1995, 26, 41-46.
5. National Kidney Foundation Study Group. NKF-DOQI clinical practice guidelines for the treatment of chronic renal failure. Am. J. Kidney Dis. 1995, 30 (Suppl. 3), S192-237.
6. Marx, J.J.M. Mucosal uptake, mucosal transfer and retention of iron, measured by whole-body counting. Scand. J. Haematol. 1979, 23, 293-302.
7. Kooistra, M.P.; Niemantsverdriet, E.C.; Es, A.M.; Mol-Beerman, E.M.; Struyvenberg, A.; Marx, J.J.M. Iron absorption in erythropoietin-treated haemodialysis patients: effects of iron availability, inflammation and aluminium. Nephrol. Dial. Transplant. 1998, 13, 82-88.
8. Kooistra, M.P.; Marx, J.J.M. The absorption of iron is disturbed in recombinant human erythropoietin-treated dialysis patients. Nephrol. Dial. Transplant. 1998, 13, 2578-2582.
9. Weber, J.; Werre, J.M.; Julius, H.W.; Marx, J.J.M. Decreased iron absorption in patients with active rheumatoid arthritis, with and without iron deficiency. Ann. Rheum. Dis. 1988, 47, 404-409.
10. Auerbach, M.; Ballard, H.; Trout, R.; McIlwain, M.; Ackerman, A.; et al. Intravenous iron optimises the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J. Clin. Oncol. 2004, 22, 1301-1307.
11. Marx, J.J.M. Normal iron absorption and decreased red cell iron uptake in the aged. Blood 1979, 53, 204-211.